Why All The Advice To Not Go Up in Dosage? 72 Week Study Shows Otherwise : r Zepbound Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet